ArticleJournal of the American Society of Nephrology : JASN2026
Eupalinolide B Ameliorates Diabetic Kidney Disease via Inhibition of Cell Division Cycle 37-Mediated Inflammatory Pathways.
Article in Journal of the American Society of Nephrology : JASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dismissing the Chaperone in the Diabetic Kidney.Journal of the American Society of Nephrology : JASN · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
key pointsA natural sesquiterpene lactone compound Eupalinolide B protected against diabetic kidney disease. Eupalinolide B targeted cell division cycle 37 protein and disrupted the interaction between cell division cycle 37 and heat shock protein 90. The renoprotective effects of Eupalinolide B were dependent on cell division cycle 37-mediated inflammatory pathways in diabetic kidney disease.
backgroundDiabetic kidney disease (DKD) is a major complication of diabetes, driven by chronic inflammation throughout its initiation and progression. Developing effective novel therapeutics is urgently needed. Eupalinolide B, a natural small compound derived from Eupatorium lindleyanum DC ., has multiple bioactive properties, notably antitumor and anti-inflammatory activities. However, the therapeutic potential of Eupalinolide B for DKD remains unclear. This study was to investigate the potential effects, direct targets, and pharmacologic mechanisms of Eupalinolide B against DKD, and discover novel therapeutic targets in the progression of DKD.
methodsThe therapeutic effects of Eupalinolide B were assessed in high glucose-induced rat mesangial (HBZY-1) cells and db/db diabetic mice. Targeting and binding site engagement of Eupalinolide B was validated through activity-based protein profiling technology, pull-down assay, surface plasmon resonance analysis, and high-resolution mass spectrometry analysis. The target protein was knocked down to investigate its role in DKD-related inflammation and determine whether Eupalinolide B's renoprotective effects depend on the protein. The impact of Eupalinolide B on protein-protein interactions was examined using immunoblotting, immunohistochemistry, immunofluorescence, and coimmunoprecipitation assays.
resultsEupalinolide B was observed to ameliorate the glomerular filtration dysfunction and histopathologic damage in db/db mice and suppress NF-κB and mitogen-activated protein kinase proinflammatory pathways in both high glucose-induced HBZY-1 cells and db/db mice. In addition, we found that Eupalinolide B directly bound to cysteine 64 and 234 residues of cell division cycle 37 (CDC37), the essential cochaperone of heat shock protein 90 (HSP90). Mechanistically, by targeting CDC37, Eupalinolide B disrupted the interaction between CDC37 and HSP90, consequently blocking downstream proinflammatory signaling upon high glucose induction in HBZY-1 cells.
conclusionsEupalinolide B was identified as a novel CDC37-targeting agent with renoprotective and anti-inflammatory effects against DKD that functions by inhibiting CDC37-HSP90 interaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.